Pawlowska, M.; Dobrowolska, K.; Moppert, J.; Pokorska-Śpiewak, M.; Purzynska, M.; Marczynska, M.; Zarebska-Michaluk, D.; Flisiak, R.
Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study. J. Clin. Med. 2023, 12, 6949.
https://doi.org/10.3390/jcm12216949
AMA Style
Pawlowska M, Dobrowolska K, Moppert J, Pokorska-Śpiewak M, Purzynska M, Marczynska M, Zarebska-Michaluk D, Flisiak R.
Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study. Journal of Clinical Medicine. 2023; 12(21):6949.
https://doi.org/10.3390/jcm12216949
Chicago/Turabian Style
Pawlowska, Malgorzata, Krystyna Dobrowolska, Justyna Moppert, Maria Pokorska-Śpiewak, Mariola Purzynska, Magdalena Marczynska, Dorota Zarebska-Michaluk, and Robert Flisiak.
2023. "Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study" Journal of Clinical Medicine 12, no. 21: 6949.
https://doi.org/10.3390/jcm12216949
APA Style
Pawlowska, M., Dobrowolska, K., Moppert, J., Pokorska-Śpiewak, M., Purzynska, M., Marczynska, M., Zarebska-Michaluk, D., & Flisiak, R.
(2023). Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study. Journal of Clinical Medicine, 12(21), 6949.
https://doi.org/10.3390/jcm12216949
